Miles White News
-
AbbVie Inc. forecast 2013 earnings higher than analysts’ estimates, after sales surged for its arthritis treatment Humira, the world’s second-best selling medicine, and its testosterone-boosting gel.
-
Abbott Laboratories and its drug- company spinoff AbbVie Inc. both gained as their shares traded on the open market for the first time as separate businesses.
-
Abbott Laboratories’ spinoff began trading on a “when issued” basis, with investors valuing the new Abbott at $47.9 billion and the new drug company AbbVie Inc. at $55.3 billion.
-
The Chicago that Richard M. Daley transformed and will hand off in May to the next mayor can be seen from the corner of Chicago Avenue and Larrabee Street.
-
Rahm Emanuel ’s relationship with unions can make even the simplest question difficult: Is the former White House chief of staff and Chicago mayoral candidate a friend of labor?
-
Abbott Laboratories, seeking to sell investors on its proposed breakup, said a pharmaceutical spinoff may gain $4 billion in extra revenue from three new therapies and expanded uses of autoimmune drug Humira.
-
Illinois , whose comptroller said the state is in the worst financial position in its history, may face a risk premium that is about 11 percent above what it paid last month when it sells $900 million of Build America Bonds today.
-
Abbott Laboratories plans to invest more in research and development in emerging markets, Chief Executive Officer Miles White said. He spoke at a Financial Times pharmaceutical industry conference in London.
-
Abbott Laboratories, the health-care company that plans to spin off its drug business, fell the most in two months after reporting fourth-quarter sales that came in below analyst estimates.
-
Rahm Emanuel , the former White House chief of staff to President Barack Obama , formally announced his plans to replace Chicago Mayor Richard M. Daley amid a narrowing field of candidates.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page